Cambridge Healthtech Institute Training Seminars offer real-life case studies, problems encountered and solutions applied, along with extensive coverage of the academic theory and background. Each Training Seminar offers a mix of formal lecture and interactive
discussions and activities to maximize the learning experience. These Training Seminars are led by experienced instructors who will focus on content applicable to your current research and provide important guidance for those new to their fields.
WEDNESDAY, SEPTEMBER 16 - THURSDAY, SEPTEMBER 17
DAY 1: 8:00 AM - 5:00 PM | DAY 2: 8:00 - 11:20 AM
TS1: Targeting GPCRs for Drug Discovery
This training seminar is designed for medicinal chemists, biologists, and scientists concentrating on discovering and developing drugs against G protein-coupled receptors (GPCRs). The challenge the seminar addresses is how to predict therapeutic activity
– because drug candidate profiles seen in in vitro test systems often do not adequately reflect in vivo responses due to the drug candidates’ interaction with variable ambient physiology. More specifically, this seminar describes the
pharmacological procedures needed to convert ‘descriptive data’ (what we see) to ‘predictive data’ (what will be seen) through universal pharmacological scales, such as affinity, efficacy, cooperativity parameters, offset
rates, etc. The desired outcome is to more fully define ligand properties to reduce attrition in late-stage drug development. Three major classes of GPCR ligands will be discussed: (1) agonists (with special reference to biased signaling); (2)
antagonists (with inverse agonists); and (3) allosteric modulators (characterization of NAMs, PAMs). I will illustrate how concepts introduced over the past 15 years have considerably expanded and revitalized the possibilities for GPCRs as therapeutic
Terry Kenakin, PhD, Professor, Department of Pharmacology, University of North Carolina School of Medicine
TS2: Introduction to Antibody Discovery and Engineering
This training seminar offers a comprehensive tutorial in the concepts, strategies, and latest tools for biotherapeutic discovery – including DNA sequencing and data analysis, DNA synthesis, single-cell isolation, and genome engineering using
CRISPR/Cas9 – then moves to an exploration of the role and stages of protein engineering in biotherapeutic research and development. The class is directed at scientists new to the industry or working in support roles, academic scientists,
and career protein scientists wanting a detailed update on the current state of the field.
David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
THURSDAY, SEPTEMBER 17 - FRIDAY, SEPTEMBER 18
DAY 1: 2:45 - 6:30 PM | DAY 2: 8:40 AM - 3:55 PM
TS3: Introduction to Small Molecule Drug Discovery and Development
This lecture-based interactive seminar focuses on strategies for identifying drug discovery targets, discovering and characterizing small molecule hits, and developing structure-activity relationships to advance hits through lead optimization,
preclinical development, and clinical evaluation. Participants will learn the stages and processes required to advance programs from idea to clinic, through examples and case studies. This seminar is intended for scientists in either academia
or industry who would like to become more familiar with small molecule drug discovery and development.
H. James Harwood Jr., PhD, Founder and CEO, Delphi BioMedical Consultants, LLC
TS4: Introduction to Structure-Based Drug Design and Development
CHI’s Introduction to Structure-Based Drug Design and Development offers an introduction to the concepts, strategies and tools of structure-based biologics design, optimization and development. The seminar consists of presentations and live
demonstrations of some of the common computational tools used in the field. We will cover techniques on how to create models of proteins (such as antibodies and membrane proteins) and use these to triage therapeutics sequences, modulate affinity,
developability and to create novel constructs (such as Fc-fusions, bispecifics, CARs). The class is directed at scientists new to the industry, academic scientists and career protein engineers wanting an introduction into how structure can
aid in guiding experimental design.
Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
Traian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, National Research Council Canada
Training Seminar Information
Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment
breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the Training Seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend
the seminar, but after these have been distributed, no additional books will be available.
Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because
seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.